These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 34028386)

  • 41. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
    Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune monitoring facilitates the clinical decision in multifocal COVID-19 of a pancreas-kidney transplant patient.
    Babel N; Anft M; Blazquez-Navarro A; Doevelaar AAN; Seibert FS; Bauer F; Rohn BJ; Hoelzer B; Thieme CJ; Roch T; Meister TL; Pfaender S; Steinmann E; Dittmer U; Schenker P; Amann K; Viebahn R; Stervbo U; Westhoff TH
    Am J Transplant; 2020 Nov; 20(11):3210-3215. PubMed ID: 32777178
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
    Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
    Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
    BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
    Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S
    Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of Kidney Transplantation on Humoral Immunity Against SARS-CoV-2: A Case Series From Belgium.
    Fernandes G; Devresse A; Scohy A; Yombi JC; Belkhir L; De Greef J; De Meyer M; Mourad M; Darius T; Buemi A; Kabamba B; Goffin E; Kanaan N
    Transplantation; 2021 Nov; 105(11):e257-e258. PubMed ID: 34347716
    [No Abstract]   [Full Text] [Related]  

  • 48. Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients.
    Haskin O; Ashkenazi-Hoffnung L; Ziv N; Borovitz Y; Dagan A; Levi S; Koren G; Hamdani G; Levi-Erez D; Landau D; Alfandary H
    Transplantation; 2021 Nov; 105(11):e226-e233. PubMed ID: 34381004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of two-dose SARS-CoV-2 vaccination
    Chen CC; Huang YJ; Lai MJ; Lin MH; Lin WC; Lin HY; Lin YC; Huang YT; Lee YF; Tsai MK; Lee CY
    Front Immunol; 2022; 13():951576. PubMed ID: 36189313
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Humoral response after a third and fourth dose of mRNA-based SARS-CoV-2 vaccine in previously seronegative kidney transplant recipients.
    Brandstetter C; Haller MC; Berger JM; Kerschner H; Apfalter P; Cejka D
    Wien Klin Wochenschr; 2022 Dec; 134(23-24):815-821. PubMed ID: 36326920
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.
    Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM
    Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Humoral Response in Kidney Transplant Recipients and Donors and Healthy Volunteers Following Second Dose of SARS-CoV-2 mRNA Vaccine.
    Sasaki H; Hasegawa K; Harada H; Takamoto D; Takada Y; Hirano T; Tanabe T; Tanaka H; Miura M
    Transplant Proc; 2023 Apr; 55(3):514-520. PubMed ID: 36948961
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
    Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
    Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
    Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
    J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experience with belatacept rescue therapy in kidney transplant recipients.
    Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
    Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron (BA.1) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease.
    Stich M; Di Cristanziano V; Tönshoff B; Weber LT; Dötsch J; Rammer MT; Rieger S; Heger E; Garbade SF; Burgmaier K; Benning L; Speer C; Habbig S; Haumann S
    Pediatr Nephrol; 2023 Jun; 38(6):1935-1948. PubMed ID: 36409368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Humoral Response After SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Role of Immunosuppression Therapy.
    López V; Polo C; Schuldt R; Vázquez T; Gutiérrez-Vílchez E; Moliz C; Hernández D
    Transplant Proc; 2022 Nov; 54(9):2454-2456. PubMed ID: 36273957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.
    Zhang H; Wang Z; Zhang J; Gui Z; Han Z; Tao J; Chen H; Sun L; Fei S; Yang H; Tan R; Chandraker A; Gu M
    Front Immunol; 2021; 12():618737. PubMed ID: 33732243
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
    Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
    Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.